

# Shu-Fu Lin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1858112/publications.pdf>

Version: 2024-02-01

31  
papers

759  
citations

516710

16  
h-index

526287

27  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1079  
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study. <i>World Journal of Clinical Cases</i> , 2021, 9, 71-80.	0.8	4
2	Efficacy of adavosertib therapy against anaplastic thyroid cancer. <i>Endocrine-Related Cancer</i> , 2021, 28, 311-324.	3.1	4
3	Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer. <i>Cancers</i> , 2021, 13, 3487.	3.7	2
4	Survival and Death Causes in Thyroid Cancer in Taiwan: A Nationwide Caseâ€“Control Cohort Study. <i>Cancers</i> , 2021, 13, 3955.	3.7	3
5	Therapeutic inhibition of poloâ€“like kinases in anaplastic thyroid cancer. <i>Cancer Science</i> , 2021, 112, 803-814.	3.9	4
6	Familial Aggregation and Heritability of Nonmedullary Thyroid Cancer in an Asian Population: A Nationwide Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2521-e2530.	3.6	8
7	<sup>1</sup> H Nuclear Magnetic Resonance (NMR)-Based Cerebrospinal Fluid and Plasma Metabolomic Analysis in Type 2 Diabetic Patients and Risk Prediction for Diabetic Microangiopathy. <i>Journal of Clinical Medicine</i> , 2019, 8, 874.	2.4	27
8	Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 727-738.	3.1	8
9	Therapeutic Outcomes of Recurrent Well-Differentiated Thyroid Carcinomas. <i>International Surgery</i> , 2019, 104, 304-313.	0.1	0
10	The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis. <i>Nuclear Medicine Communications</i> , 2018, 39, 1091-1096.	1.1	14
11	Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, 853-864.	3.1	9
12	Activity of roniciclib in medullary thyroid cancer. <i>Oncotarget</i> , 2018, 9, 28030-28041.	1.8	16
13	A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. <i>PLoS ONE</i> , 2017, 12, e0172315.	2.5	36
14	Maternal and fetal outcomes of pregnant women with type 1 diabetes, a national population study. <i>Oncotarget</i> , 2017, 8, 80679-80687.	1.8	15
15	Long-term follow-up of papillary and follicular thyroid carcinomas with bone metastasis. <i>PLoS ONE</i> , 2017, 12, e0173354.	2.5	23
16	Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. <i>Oncotarget</i> , 2017, 8, 41294-41304.	1.8	33
17	Effects of roniciclib in preclinical models of anaplastic thyroid cancer. <i>Oncotarget</i> , 2017, 8, 67990-68000.	1.8	8
18	Nationwide cohort study on the epidemiology and survival outcomes of thyroid cancer. <i>Oncotarget</i> , 2017, 8, 78429-78451.	1.8	45

#	ARTICLE	IF	CITATIONS
19	Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice. <i>Synergy</i> , 2016, 3, 15-30.	1.1	45
20	MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential. <i>Cancer Letters</i> , 2015, 369, 76-85.	7.2	29
21	Epithelial-Mesenchymal Transition Enhances Response to Oncolytic Herpesviral Therapy Through Nectin-1. <i>Human Gene Therapy</i> , 2014, 25, 539-551.	2.7	14
22	Prognosis of Multifocal Papillary Thyroid Carcinoma. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-6.	1.5	45
23	Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment. <i>PLoS ONE</i> , 2013, 8, e77684.	2.5	35
24	Therapeutic outcome and prognosis in young patients with papillary and follicular thyroid cancer. <i>Pediatric Surgery International</i> , 2012, 28, 489-494.	1.4	16
25	Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy. <i>PLoS ONE</i> , 2012, 7, e46726.	2.5	38
26	Novel Oncolytic Agent GLV-1h68 Is Effective Against Malignant Pleural Mesothelioma. <i>Human Gene Therapy</i> , 2008, 19, 774-782.	2.7	67
27	Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1519-1528.	7.0	57
28	Sensitivity of Squamous Cell Carcinoma Lymph Node Metastases to Herpes Oncolytic Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 1897-1904.	7.0	12
29	Oncolytic Vaccinia Virotherapy of Anaplastic Thyroid Cancer <i>in Vivo</i> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4403-4407.	3.6	54
30	Nectin-1 Is a Marker of Thyroid Cancer Sensitivity to Herpes Oncolytic Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1965-1970.	3.6	42
31	Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. <i>Surgery</i> , 2007, 142, 976-983.	1.9	46